COCLICAN · COllaborative Consortium for the early detection of LIver CANcer
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2018-11-01 → 2022-10-31
- EU contribution
- €450,800
- Participants
- 8
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
COllaborative Consortium for the early detection of LIver CANcer
Liver cancer is a significant cause of illness and early death, especially in developing countries where there is difficulty accessing diagnostic technology. In the coming decades, it is likely that this disease will cause a major challenge in global public health, and create a burden to society through illness and death which could be prevented with earlier diagnosis. Incidence of HCC is closely associated with prevalence of the hepatitis B (HBV) and C (HCV) viruses. Clinically, HCC patients have a very poor prognosis and high 5-year mortality rate, except when detected early. Detecting HCC early is critical in order to prevent the development of tumours. Affordable and accurate diagnostic tools are urgently needed to diagnose liver cancer earlier in developing countries. The COCLICAN project aims to develop effective methods for early diagnosis which can be used at a low cost to medical institutions and patients. The project brought together a collaborative network of researchers and clinicians in three continents: Europe, South America and Asia. With field sites in Peru and Laos, where liver cancer is an emergent threat to the health of the population, this international team had analysed and compare metabolomic profiles of a consistent cohort of HBV-HBC infected patients to delineate molecules which are predictive of the emergence of liver cancer.
Data: CORDIS, © European Union
Project objective
Hepatitis B (HBV) and C virus (HCV) are the most important etiologic agents of Hepatocellular carcinoma (HCC), which is the second leading cause of tumour related death in the world. The burden of HCC in developing countries represents a major challenge in global public health for the oncoming decades. Clinically, HCC patients have a very poor prognosis and high 5-year mortality rate except when detected early. As a result, HCC early detection is a critical parameter to anticipate the initiation of a tumour process, but affordable and discriminant diagnostic tools are lacking. A consortium of European and Third Countries institutions (Peru and Laos) gathered within the project COCLICAN proposes to tackle this issue through the analysis of metabolomics serum profiles of a large cohort of HBV-HBC infected patients to delineate a bunch of molecules predictive of the emergence of liver cancer. The performance of a low-cost and open-source echo-stethoscope connected to a smartphone will also be assessed, to allow early detection of tumorogenesis in health care underserved areas. This will be possible, thanks to the construction of a sustainable scientific and academic network of engineers, researchers and clinicians mobilised to exchange expertise, skills, technologies, biological material, deployed in three continents: Europe, South America and Asia. COCLICAN has been designed to improve research collaborations, to reinforce capacities, to enhance knowledge of partners and students involved in the project, but also to raise awareness of policy makers and to participate to the innovation potential improvement at the European and global levels. COCLICAN will therefore respond to the health needs of left behind populations, all around the world.
Original text from CORDIS.
Participants
- INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT · MarseilleCoordinatorFrance
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS · ParisFrance
- FONDATION MERIEUX · LyonFrance
- INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN · LimaPeru
- KAUNO TECHNOLOGIJOS UNIVERSITETAS · KaunasLithuania
- MINISTRY OF HEALTH · LAOCountry levelLaos
- UNIVERSITE LIBRE DE BRUXELLES · Bruxelles / BrusselBelgium
- UNIVERSITE PAUL SABATIER TOULOUSE III · Toulouse Cedex 9France
Links
Data: CORDIS, © European Union